Citations

Clear

16280 citation(s) found for "Yu, David".

Expert consensus recommendations on dermoscopy proficiency standards for physician assistants: results of a modified Delphi survey
Young, Peter A. , Middleton, Hayden T. , Froiland, Christi, Keeter, Nicole, Sanders, Kim B., DiRuggiero, Douglas , Pettey, Adam A., Swanson, David C. , Marghoob, Ashfaq A. , McCleskey, Patrick E. , Seiverling, Elizabeth V. , Griffith, Cynthia Faires , Sanders, Kim B., Bae, Gordon Hyeonjin , Mostaghimi, Arash , Nelson, Kelly C.

Mayo Clinic

Journal of Dermatology for Physician Assistants | December 25, 2024 | Volume: 19 | Issue: 1 | Pages: 14-19

10.1097/jdpa.0000000000000047 Get It

Importance: Dermoscopy is increasingly recognized by skin cancer experts and professional leaders as an essential skill for physicians in dermatology and primary care. A substantial number of patients in both settings also receive care from physician assistants (PAs), who provide additional opportunities to evaluate patients with concerning skin lesions. Earning dermatology-specific credentials from the National Commission on Certification for PAs requires passing a written exam with dermoscopic content, and 77% of practicing PAs (all specialties) believe dermoscopy should be a standard element of their formal education. No published studies have identified precise learning objectives that would represent appropriate foundational proficiency in dermoscopy for PAs. Objective: We sought to identify common diagnoses with distinct dermoscopic features and delineate which of these represent appropriate proficiency expectations for early-career PAs in primary care and dermatology. Design, setting, and participants: A panel of 14 dermoscopists was assembled (8 dermatologists; 6 PAs), reflecting contributors to existing consensus statements on physician dermoscopy proficiency benchmarks, dermatologist-recommended competencies for PAs, and/or standardized test content for dermatology PAs. Panelists completed a modified Delphi consensus process involving electronic surveys and roundtable discussions. Main outcomes and measures: Consensus on which specific dermoscopic diagnoses reflect appropriate foundational proficiency expectations for PAs in both primary care and dermatology. Results: Twelve of 14 panelists (86%) reported using dermoscopy for over 12 years (mean: 15.5 y). All panelists completed 2 iterations of an electronic survey regarding 54 diagnoses, with 39 (72%) reaching a final consensus for inclusion in PA curricula and 15 (28%) being identified as non-priority items for early-career PAs. Panelists recommended 14 conditions for primary care PAs and 25 conditions for dermatology PAs. Conclusions and Relevance: Consensus achieved in this modified Delphi process identified diagnoses that represent pragmatic learning objectives to achieve foundational proficiency in dermoscopy for PAs in both primary care and dermatology. This list of validated objectives provides a consensus-based guide to help educators, supervising physicians, and professional leaders to cultivate specialty-appropriate dermoscopic proficiency among early-career PAs.
Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis
Katz, Philip O. , DeVault, Kenneth R. , Metz, David C., Tamene, David, Smith, Neila, Hunt, Barbara, Katz, Philip , Howden, Colin W. , Chang, Yu‐Ming , Spechler, Stuart Jon

Mayo Clinic

Alimentary Pharmacology & Therapeutics | December 25, 2024 | Volume: 61 | Issue: 5 | Pages: 835-851

10.1111/apt.18458 | PMID 39720884 Get It

ABSTRACT Background Patients with erosive oesophagitis, and those with persistent symptomatic non‐erosive gastro‐oesophageal reflux disease, require long‐term maintenance treatment with acid‐suppressing agents. Aim To evaluate the safety of vonoprazan, a potassium‐competitive acid blocker, in an integrated analysis of data from clinical trials in adults. Methods We included 14 clinical trials of vonoprazan conducted in multiple countries. Mean duration of exposure in person‐years to vonoprazan ( n = 5318) was 2068, to comparators lansoprazole ( n = 1925) or esomeprazole ( n = 86) was 751, and to placebo ( n = 779) was 59. We report adverse events, serum gastrin, and liver enzyme levels as the main outcomes. Post‐marketing safety data from December 26, 2014 (date of commercialisation in Japan) to December 25, 2023, are also provided. Results Nasopharyngitis was the only adverse event reported by at least 5.0% of patients (6.94% vonoprazan, 5.07% proton pump inhibitor (PPI), 4.49% placebo). Incidence rates per 100 person‐years for serious adverse events were 10.39 for vonoprazan, 10.65 for PPIs, and 1.69 for placebo. One patient each on vonoprazan and lansoprazole was diagnosed with gastric cancer. Mean serum gastrin levels were higher on vonoprazan than lansoprazole but normalised by 4 weeks after discontinuation. Elevated liver enzyme levels were infrequent and of low magnitude with no differences between vonoprazan and PPIs. There were four deaths; none was considered related to study drug. Conclusions Vonoprazan was well tolerated. Its safety profile from both clinical trial and post‐marketing data were consistent and comparable to that of its PPI comparators with respect to treatment‐emergent adverse events.
DEK::AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma
Hart, Stephanie A , Mikula, Michael W. , Amin, Sara E. , Saluja, Karan , Chen, Y., David, Stephanie N., Dupont, William D., Plummer, W. Dale, Ferrer, Karen, Geromes, Ariana, Hsieh, Min-Shu, Kuo, Ying‐Ju , Sasaki, Eiichi , Shi, Qiuying , Truong, Tra , Lewis, James S. , Lewis, James S , Hang, Jen‐Fan , Chernock, Rebecca , Rooper, Lisa M. , Bishop, Justin A. , Cipriani, Nicole A. , Hsieh, Min‐Shu , Hernandez‐Prera, Juan C. , Torres, Jaylou M. Velez

Mayo Clinic

American Journal of Surgical Pathology | December 25, 2024 | Volume: 49 | Issue: 2 | Pages: 130-137

10.1097/pas.0000000000002335 | PMID 39719672 Get It

DEK::AFF2 fusion nonkeratinizing squamous cell carcinoma (NKSCC) is an emerging entity in the sinonasal tract, temporal bone, and skull base. However, the clinical behavior of these tumors has not been well studied. Here, we report the largest cohort of DEK::AFF2 carcinomas to determine if morphology, mitotic rate, and/or Ki-67 IHC are associated with patient outcomes, including a comparison with high-risk human papillomavirus (HPV)-associated and independent patients. We solicited cases of molecularly or AFF2 immunohistochemistry (IHC) proven DEK::AFF2 SCC from surgical pathologists to collect patient demographic, clinical, and outcome data. Using representative H&E slides, we characterized the morphology and counted mitoses. Ki-67 immunohistochemistry was performed. We also compared the DEK::AFF2 survival rates to those in a cohort of AFF2 IHC-negative HPV-associated and HPV-independent SCC. DEK::AFF2 carcinomas most commonly arose in the nasal cavity (13/30, 43%), and the average number of recurrences was 1.8 (range: 0 to 10). At the last follow-up, most patients were disease free (19/30, 63%) or were alive with disease (9/30, 30%). There was an average mitotic rate of 2 per 2 mm2 (range: 0 to 9) and Ki-67 proliferation rate of 26% (range: 3% to 60%). Local recurrence was common, but morphology, mitotic activity, and Ki-67 index were not associated with recurrence or survival. On Kaplan-Meier survival analysis, DEK::AFF2 patients had lower disease-free survival but otherwise had similar outcomes to conventional SCC patients. Our multi-institutional study shows that local recurrence is common in DEK::AFF2 fusion nonkeratinizing SCC patients, but patients have survival rates similar to conventional SCC. Despite showing a range of different features and proliferation rates, traditional grading by morphology, mitotic rate, and/or Ki-67 activity does not seem to be predictive of outcome.
Multiparametric Assessment of Right Ventricular Dysfunction in Heart Failure: An Analysis From PARAGON‐HF
Lu, Henri , Inciardi, Riccardo M. , Abanda, Martin Hongieh , Shah, Amil M. , Čikeš, Maja , Claggett, Brian , Prasad, Narayana , Lam, Carolyn S.P. , Redfield, Margaret M. , McMurray, John J.V. , Solomon, Scott D. , Abanda, Martin , Claggett, Brian L , Redfield, Margaret M , Pfeffer, Marc Alan , Solomon, Scott David , Hegde, Sheila M , Skali, Hicham , McMurray, John J V , Lam, Carolyn S P , Shah, Amil , Hegde, Sheila M. , Skali, Hicham

Mayo Clinic

Journal of the American Heart Association | December 24, 2024 | Volume: 14 | Issue: 1 | Pages: No page available

10.1161/jaha.124.037380 | PMID 39719412 Get It

Background This study aims to characterize right ventricular dysfunction (RVD) in heart failure (HF) with preserved ejection fraction and understand the cumulative prognostic value of abnormal RV echocardiographic parameters in HF with preserved ejection fraction. Methods and Results Data from 809 patients in the PARAGON‐HF (Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor With Angiotensin‐Receptor Blocker Global Outcomes in HF With Preserved Ejection Fraction) echocardiographic substudy (55% women, mean age 74±8 years) were analyzed. Correlates of RVD (defined as tricuspid annular plane systolic excursion <1.7 cm, fractional area change <35% or absolute RV free wall longitudinal strain <20%) were identified using multivariable logistic regression models. We further assessed the prognostic value of the number of abnormal RV parameters (0, 1, ≥2) on total HF hospitalizations (HFH) and cardiovascular death, total HFH, first HFH or cardiovascular death, all‐cause death, and cardiovascular death. RVD was identified in 461 (57%) patients. Correlates of RVD included older age, higher heart rate, atrial fibrillation/flutter, greater left ventricle wall thickness, higher N‐terminal pro‐B‐type natriuretic peptide levels, lower systolic blood pressure, and lower left ventricle absolute global longitudinal strain. These results were consistent across sexes, except atrial fibrillation/flutter and LV wall thickness, which were associated with a higher risk of RVD in men but not in women. Participants with ≥2 abnormal RV parameters had a significantly higher adjusted risk of total HFH and cardiovascular death (rate ratio, 2.13 [95% CI, 1.13–4.01]), first HFH or cardiovascular death, all‐cause death, and cardiovascular death. Conversely, an isolated abnormal RV parameter was not associated with a worse outcome. Conclusions RV measures may underestimate the burden of RVD in HF with preserved ejection fraction when considered in isolation. Clinicians should consider multiple dimensions to comprehensively assess RV function in patients with HF with preserved ejection fraction.
Precision diagnosis of cognitive impairment due to Alzheimer's disease for therapeutic interventions
Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | December 24, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14043 | PMID 39718338 Get It

Abstract With the advent of anti‐amyloid monoclonal antibody (AAMA) therapy, precision diagnosis is necessary for identifying appropriate patients with cognitive disorders due to Alzheimer's disease. Therapy with AAMAs requires that candidates be diagnosed with mild cognitive impairment or mild dementia, have elevated brain amyloid‐β, have good physical, psychiatric, and medical health, and lack clinical or biomarker evidence of potentially impactful non‐Alzheimer brain disorders. The first three diagnostic activities are the core of the Clinical Practice Guidelines, but the last element of the precision diagnosis requires new decision‐making tools for recognizing multi‐etiology cognitive impairment. Within the context of shared decision‐making between clinician, patient, and family, proper diagnosis is essential. In addition to discussing the benefits and risks of AAMA therapy, the experienced clinician must empathetically assist in bridging the gap between expectations of benefit and the patient's overall diagnostic suitability for AAMA therapy. Highlights In order to prescribe an anti‐amyloid monoclonal antibody (AAMA) to the right patients, those selected for treatment should be diagnosed with mild cognitive impairment or mild dementia, have elevated brain amyloid‐β (Aβ), and have good physical, psychiatric, or medical health. Persons with Alzheimer's biology as the primary etiology are the ideal AAMA treatment recipients. A novel activity necessary to optimize therapeutic response is to exclude persons with clinical or biomarker evidence of alternative contributory brain disorders. While mild clinical severity and elevated brain amyloid‐β are essential elements for selecting patients for AAMA treatment, clinical judgment is required to weigh the implications of more advanced disease severity, other medical co‐morbidities, and the presence of other contributory neuropathologies.
Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Riviere-Cazaux, Cécile , Dong, Xiaoxi , Mo, Wei , Kumar, Rahul , Dai, Chao , Carlstrom, Lucas P. , Munoz-Casabella, Amanda , Nesvick, Cody L. , Andersen, Katherine M., Hoplin, Matthew D. , Canaday, Nicholas, Jusué-Torres, Ignacio , Malik, Noor , Campian, Jian L., Ruff, Michael W. , Uhm, Joon H. , Eckel‐Passow, Jeanette E. , Kizilbash, Sani H. , Warrington, Arthur E. , Jenkins, Robert B. , Du, Pan , Jia, Shidong , Ghadimi, Keyvan , Nesvick, Cody L , Andersen, Katherine M , Hoplin, Matthew D , Canaday, Nicholas , Jusue-Torres, Ignacio , Malik, Noor , Campian, Jian L , Ruff, Michael W , Uhm, Joon H , Eckel-Passow, Jeanette E , Kaufmann, Timothy J , Routman, David M , Kizilbash, Sani H , Sener, Ugur , Warrington, Arthur E , Jenkins, RB , Du, Pan , Jia, Shidong , Burns, Terry C , Kumar, Rahul , Kaufmann, Timothy J. , Routman, David M. , Sener, Uğur , Burns, Terry C.

Mayo Clinic

Clinical Cancer Research | December 23, 2024 | Volume: 31 | Issue: 5 | Pages: 881-889

10.1158/1078-0432.ccr-24-1814 | PMID 39715486 Get It

Abstract Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with gliomas. Experimental Design: Adults with gliomas underwent longitudinal intracranial CSF collection via Ommaya reservoirs or ventriculoperitoneal shunts. Cell-free DNA (cfDNA) was extracted and analyzed using PredicineCARE for cancer variant profiling and/or PredicineSCORE for low-pass whole-genome sequencing. Results: Five patients (two females and three males; median age, 40 years; range, 32–64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n = 4) or ventriculoperitoneal shunts (n = 1). In total, 47 CSF samples were obtained (median volume, 4.00 mL; 0.5–5 mL). Forty-one samples (87.2%) yielded sufficient cfDNA for testing. Patient-specific tumor-associated variant allelic frequencies (VAF), and thus tumor fraction, decreased in pre- versus postchemoradiation samples, including through pseudoprogression. These also increased with radiographic progression in three patients, although identifying the time of definitive disease progression from MRIs was a significant limitation. In two patients with isocitrate dehydrogenase (IDH)–mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate levels (0.64× and 0.62×, respectively, for the first patient and 0.01× and 0.07× for the other patient), although D-2-hydroxyglutarate and IDH1 VAF were not concordant in one patient thereafter. Moreover, the copy-number burden decreased below the limit of quantification during treatment and increased above the limit at progression. Conclusions: Longitudinal intracranial CSF cfDNA can be obtained in patients with gliomas during their disease course. However, before deploying this technique, numerous questions and challenges should be answered.
cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics
Aldape, Kenneth , Capper, David , Giannini, Caterina , Gilbert, Mark R. , Hawkins, Cynthia , Hench, Juergen , Jacques, Thomas S. , Louis, David N. , Mueller, Sabine , Nasrallah, MacLean P. , Solomon, David A. , von Deimling, Andreas , Giannini, Caterina , Gilbert, M. Jean , Hawkins, Cynthia , Hench, Jürgen , Jacques, Thomas S , Orr, Brent A , Nasrallah, MacLean , Pfister, Stefan M , Sahm, Felix , Snuderl, Matija , Varlet, Pascale , Solomon, David A , Capper, David , Deimling, Andreas von , Jones, David , Orr, Brent A. , Pfister, Stefan M. , Sahm, Felix , Snuderl, Matija , Wesseling, Pieter

Mayo Clinic

Neuro-Oncology Advances | December 23, 2024 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdae228 | PMID 39902391 Get It

Abstract Genome-wide DNA methylation signatures correlate with and distinguish central nervous system (CNS) tumor types. Since the publication of the initial CNS tumor DNA methylation classifier in 2018, this platform has been increasingly used as a diagnostic tool for CNS tumors, with multiple studies showing the value and utility of DNA methylation-based classification of CNS tumors. A Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) Working Group was therefore convened to describe the current state of the field and to provide advice based on lessons learned to date. Here, we provide recommendations for the use of DNA methylation-based classification in CNS tumor diagnostics, emphasizing the attributes and limitations of the modality. We emphasize that the methylation classifier is one diagnostic tool to be used alongside previously established diagnostic tools in a fully integrated fashion. In addition, we provide examples of the inclusion of DNA methylation data within the layered diagnostic reporting format endorsed by the World Health Organization (WHO) and the International Collaboration on Cancer Reporting. We emphasize the need for backward compatibility of future platforms to enable accumulated data to be compatible with new versions of the array. Finally, we outline the specific connections between methylation classes and CNS WHO tumor types to aid in the interpretation of classifier results. It is hoped that this update will assist the neuro-oncology community in the interpretation of DNA methylation classifier results to facilitate the accurate diagnosis of CNS tumors and thereby help guide patient management.
Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for primary care
Clevenger, Carolyn , Karlawish, Jason , Lin, Pei‐Jung , Norman, Mary S., Onyike, Chiadi U. , Sano, Mary , Scanland, Susan, Carrillo, María C. , Atri, Alireza , Dickerson, Bradford Clark , Knopman, David S. , Norman, Mary

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.14333 | PMID 39713942 Get It

Abstract US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. Through a modified‐Delphi approach and guideline‐development process (7374 publications were reviewed; 133 met inclusion criteria) an expert workgroup developed recommendations as steps in a patient‐centered evaluation process. This summary focuses on recommendations, appropriate for any practice setting, forming core elements of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes specialist recommendations. If clinicians use this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings. Highlights US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. This summary focuses on recommendations, appropriate for any practice setting, forming core elements of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes specialist recommendations. If clinicians use this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings.
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for specialty care
Clevenger, Carolyn , Karlawish, Jason , Lin, Pei‐Jung , Norman, Mary S., Onyike, Chiadi U. , Sano, Mary , Scanland, Susan, Carrillo, María C. , Dickerson, Bradford Clark , Atri, Alireza , Knopman, David S. , Norman, Mary

Mayo Clinic

Alzheimer's & Dementia | December 23, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14337 | PMID 39713957 Get It

Abstract US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or a related dementia (ADRD) are two decades old. This evidence‐based guideline was developed to empower all clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. An expert workgroup conducted a review of 7374 publications (133 met inclusion criteria) and developed recommendations as steps in an evaluation process. This summary briefly reviews core recommendations and details specialist recommendations of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes primary care recommendations. If clinicians use the recommendations in this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings. Highlights US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. This summary focuses on recommendations appropriate for specialty practice settings, forming key elements of a high‐quality, evidence‐supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive–behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes primary care recommendations. If clinicians use this guideline and health‐care systems provide adequate resources, outcomes should improve in most patients in most practice settings.